These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 24860567)

  • 41. Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.
    Swart M; Verbrugge I; Beltman JB
    Front Oncol; 2016; 6():233. PubMed ID: 27847783
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 43. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
    Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
    Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
    Ma W; Gilligan BM; Yuan J; Li T
    J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A snapshot of the PD-1/PD-L1 pathway.
    Ghosh C; Luong G; Sun Y
    J Cancer; 2021; 12(9):2735-2746. PubMed ID: 33854633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms.
    Planès R; BenMohamed L; Leghmari K; Delobel P; Izopet J; Bahraoui E
    J Virol; 2014 Jun; 88(12):6672-89. PubMed ID: 24696476
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer.
    Xu J; Xu L; Wang C; Yang R; Zhuang Q; Han X; Dong Z; Zhu W; Peng R; Liu Z
    ACS Nano; 2017 May; 11(5):4463-4474. PubMed ID: 28362496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
    Herrmann M; Krupka C; Deiser K; Brauchle B; Marcinek A; Ogrinc Wagner A; Rataj F; Mocikat R; Metzeler KH; Spiekermann K; Kobold S; Fenn NC; Hopfner KP; Subklewe M
    Blood; 2018 Dec; 132(23):2484-2494. PubMed ID: 30275109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An Immunophenotyping of Ovarian Cancer With Clinical and Immunological Significance.
    Yang K; Zhao W; Lou G; Rong Z; Xu H; Wang W; Song W; Cai Y; Hou Y; Li K
    Front Immunol; 2018; 9():757. PubMed ID: 32793247
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.
    Li X; Wang R; Fan P; Yao X; Qin L; Peng Y; Ma M; Asley N; Chang X; Feng Y; Hu Y; Zhang Y; Li C; Fanning G; Jones S; Verrill C; Maldonado-Perez D; Sopp P; Waugh C; Taylor S; Mcgowan S; Cerundolo V; Conlon C; McMichael A; Lu S; Wang X; Li N; Dong T
    Front Oncol; 2019; 9():1066. PubMed ID: 31709176
    [No Abstract]   [Full Text] [Related]  

  • 54. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Silva R; Gullo I; Carneiro F
    Porto Biomed J; 2016; 1(1):4-11. PubMed ID: 32258540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.
    Migali C; Milano M; Trapani D; Criscitiello C; Esposito A; Locatelli M; Minchella I; Curigliano G
    Ther Adv Med Oncol; 2016 Sep; 8(5):360-74. PubMed ID: 27583028
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top".
    Simonelli M; Persico P; Perrino M; Zucali PA; Navarria P; Pessina F; Scorsetti M; Bello L; Santoro A
    Cancer Treat Rev; 2018 Sep; 69():121-131. PubMed ID: 29966936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm.
    Rao M; Valentini D; Dodoo E; Zumla A; Maeurer M
    Int J Infect Dis; 2017 Mar; 56():221-228. PubMed ID: 28163164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Translation of cancer immunotherapy from the bench to the bedside.
    Guo Q; Huang F; Goncalves C; Del Rincón SV; Miller WH
    Adv Cancer Res; 2019; 143():1-62. PubMed ID: 31202357
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Next generation of immune checkpoint inhibitors and beyond.
    Marin-Acevedo JA; Kimbrough EO; Lou Y
    J Hematol Oncol; 2021 Mar; 14(1):45. PubMed ID: 33741032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.